Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer

Lung, Respiratory and Thoracic Cancer

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial

JAMA Oncol.

Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H

doi: 10.1001/jamaoncol.2020.1250.

Lung, Respiratory and Thoracic Cancer

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

Crit Rev Oncol Hematol.

Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, Bertolini F, Barbieri F, Cascinu S

doi: 10.1016/j.critrevonc.

Lung, Respiratory and Thoracic Cancer

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

J Clin Oncol.

Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA

doi: 10.1200/JCO.2017.74.7576.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Lung, Respiratory and Thoracic Cancer

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Lancet Respir Med.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group

doi: 10.1016/

Lung, Respiratory and Thoracic Cancer

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study.

Future Oncol.

Girard N, Moro-Sibilot D, Bouée S, Emery C, Torreton E, Le Lay K, Luciani L, Maritaz C, Chouaid C

doi: 10.2217/fon-2020-0084.

Lung, Respiratory and Thoracic Cancer

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Eur J Cancer

Tanaka K, Asahina H, Kishimoto J, Miyata Y, Uchida T, Watanabe K, Hamai K, Harada T, Tsubata Y, Sugawara S, Kobayashi K, Sugio K, Oizumi S, Okamoto I

doi: 10.1016/j.ejca.2021.02.019

Lung, Respiratory and Thoracic Cancer

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lancet Oncol.

Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G

doi: 10.1016/S1470-2045(19)30785-5.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

Lung Cancer.

Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E

doi: 10.1016/j.lungcan.2019.09.019.

Related content

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study.

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study